New York, February 24, 2026, 18:26 (EST) — After-hours
- LLY slid 1.6% at the close, with little movement in after-hours trading
- The FDA has cleared a four-dose Zepbound “KwikPen,” allowing patients to get a full month’s supply of injections from a single device.
- Traders digested new cues on obesity-drug pricing, along with competitive moves from Novo Nordisk.
Eli Lilly and Company ended Tuesday down 1.6% at $1,042.15, before ticking up 0.1% to $1,043 in after-hours moves. Shares eased off after two volatile sessions, trading between $1,024.08 and $1,058.90 during the day. 1
This is significant: Lilly’s obesity unit now drives the stock, and lately, the market’s been reacting to even modest developments—a device update, a clinical-trial chart, a headline about pricing.
Demand isn’t the only factor here. Investors are eyeing how U.S. prices and reimbursement shake out, since the sticker price often directs rebates and ends up determining what insured patients owe from their own pockets.
Lilly on Monday announced it has gotten FDA clearance to roll out a four-dose KwikPen for Zepbound, its weight-loss medication. The device covers an entire month’s supply in a single pen. Pricing for cash customers starts at $299 a month for the 2.5-milligram option, with Lilly offering six different dose strengths. By comparison, Novo Nordisk’s Wegovy comes in the U.S. market as a single-dose weekly pen. 2
The previous session saw the stock jump, as attention turned to Novo’s misstep in its pipeline. Novo on Monday released late-stage results for its obesity drug CagriSema, which showed 23% weight loss after 84 weeks—falling short of the 25.5% achieved by Lilly’s tirzepatide in a head-to-head comparison. Novo shares slid, Lilly rallied around 5%. “They literally ran a trial that said that Lilly’s product is better,” said BMO Capital Markets analyst Evan Seigerman. Over at Deutsche Bank, analysts noted the market would “likely to coalesce around Lilly’s portfolio.” Lilly now anticipates U.S. approval for its competing weight-loss pill in April. 3
Then the price tape hit. On Tuesday, Novo said it would slash U.S. list prices for Ozempic and Wegovy by as much as 50%, down to $675 a month, starting Jan. 1, 2027. The move lines up with new Medicare pricing and, according to the company, won’t touch its direct-to-patient self-pay prices. “The new $675 list price is a proactive move, specifically designed to help patients whose out-of-pocket costs are linked to list price,” said Jamey Millar, executive vice president of U.S. operations at Novo Nordisk. Citi’s Geoffrey Meacham weighed in, pointing out the price cut probably benefits only a narrow group of new prescriptions, not the cash-pay crowd. Bernstein analyst Courtney Breen dismissed talk of a price war, despite growing pressure from compounded versions sold by telehealth outfits like Hims & Hers. 4
Lilly finds itself with a pair of stories in play. The stock gets a lift from stronger trial results and the ease of its pen device, yet Novo’s cheaper offering throws cost into sharper focus, hinting the next round will center on price competition.
Zepbound and Mounjaro both use tirzepatide, a drug that affects hormones tied to appetite and blood sugar. Wegovy and Ozempic, on the other hand, are built on semaglutide—these drugs fall into the GLP-1 category, originally diabetes treatments but also widely used for weight loss.
The risk scenario’s pretty clear: should list-price reductions drag down rebates industrywide, or if insurers ramp up pressure amid broader competition, stocks can take a hit fast—even when prescriptions are holding up.
Now, attention shifts to the FDA’s decision window for Lilly’s obesity pill, slated for April. Traders are also scanning for early signals on the speed of Zepbound’s multi-dose pen rollout into the cash-pay market. Any fresh indications about how pricing resets might ripple into 2027 are likely to keep the tape on edge.
